Combining Pi3k, Cdk4/6 Pathway Inhibitors and Checkpoint Blockade in Triple-Negative Breast Cancer

Abstract

Triple-negative breast cancer (TNBC) has the worst prognosis of all breast cancer subtypes, classically affecting young women and characterized by a lack of effective therapies. We show that blocking both PI3K and CDK4/6 pathways together effectively reduces TNBC growth in mice and can enhance anti-tumour immune responses. We aim to understand how these drugs work together and if adding immunotherapy can improve responses. Our project could provide a new treatment approach for TNBC patients.

Related publications (1)

Combined CDK4/6 and PI3Kα inhibition is synergistic and immunogenic in triple-negative breast cancer

ZL Teo, S Versaci, S Dushyanthen, F Caramia, P Savas, CP Mintoff, M Zethoven, B Virassamy, SJ Luen, GA McArthur, WA Phillips, PK Darcy, S Loi

2017-11-15

New treatments for triple-negative breast cancer (TNBC) are urgently needed. Despite there being little evidence of clinical activ..